Baseline demographics and disease characteristics
| Characteristic . | Cohorts 1a and 1b (N = 125) . | Cohort 1a21 (N = 34) . |
|---|---|---|
| Age (y), median (range) | 69 (34-86) | 68 (42-86) |
| Sex, n (%) | ||
| Male | 80 (64) | 23 (68) |
| Female | 45 (36) | 11 (32) |
| Race, n (%) | ||
| White | 108 (86) | 32 (94) |
| Black or African American | 2 (2) | 2 (6) |
| Asian | 15 (12) | 0 (0) |
| ECOG performance status, n (%) | ||
| 0 | 52 (42) | 16 (47) |
| 1 | 67 (54) | 18 (53) |
| 2 | 6 (5) | 0 (0) |
| Prior lines of therapy for MF, median (range) | 1 (1-6) | 1 (1-6) |
| Baseline platelet count (×109/L), median (range) | 201 (75-1469) | 201 (98-706) |
| Baseline spleen volume (cm3), median (range) | 2128 (448∗-6219) | 1695 (466-5047) |
| Baseline white blood cell count (×109/L), median (range) | 15 (2-205) | 19 (5-205) |
| Baseline hemoglobin (g/dL), median (range) | 10 (5-15) | 11 (7-15) |
| Baseline hemoglobin ≥8 to <10 g/dL, n (%) | 34 (27) | 6 (18) |
| Transfusion status, n (%) | ||
| Dependent | 6 (13) | 4 (12) |
| Independent | 109 (87) | 30 (88) |
| Transfusion required ≤12 wk before study entry | 32 (26) | 6 (18) |
| Baseline TSS, median (range) | 17 (0-58) | 14 (0-35) |
| Time from diagnosis to study entry (mo), median (range) | 43 (1-338) | 28 (1-199) |
| Duration of prior ruxolitinib exposure for MF treatment (wk), median (range) | 95 (8-464) | 70 (13-391) |
| DIPSS risk at study entry, n (%) | ||
| Intermediate-1 | 36 (29) | 17 (50) |
| Intermediate-2 | 71 (57) | 12 (35) |
| High | 17 (14) | 4 (12) |
| JAK2 status at study entry, n (%) | ||
| Detected | 84 (72) | 25 (78) |
| CALR status at study entry, n (%) | ||
| Detected | 26 (22) | 7 (22) |
| MPL status at study entry, n (%) | ||
| Detected | 3 (3) | 0 (0) |
| HMR status at study entry† , n (%) | ||
| Detected | 71 (61) | 19 (59) |
| Characteristic . | Cohorts 1a and 1b (N = 125) . | Cohort 1a21 (N = 34) . |
|---|---|---|
| Age (y), median (range) | 69 (34-86) | 68 (42-86) |
| Sex, n (%) | ||
| Male | 80 (64) | 23 (68) |
| Female | 45 (36) | 11 (32) |
| Race, n (%) | ||
| White | 108 (86) | 32 (94) |
| Black or African American | 2 (2) | 2 (6) |
| Asian | 15 (12) | 0 (0) |
| ECOG performance status, n (%) | ||
| 0 | 52 (42) | 16 (47) |
| 1 | 67 (54) | 18 (53) |
| 2 | 6 (5) | 0 (0) |
| Prior lines of therapy for MF, median (range) | 1 (1-6) | 1 (1-6) |
| Baseline platelet count (×109/L), median (range) | 201 (75-1469) | 201 (98-706) |
| Baseline spleen volume (cm3), median (range) | 2128 (448∗-6219) | 1695 (466-5047) |
| Baseline white blood cell count (×109/L), median (range) | 15 (2-205) | 19 (5-205) |
| Baseline hemoglobin (g/dL), median (range) | 10 (5-15) | 11 (7-15) |
| Baseline hemoglobin ≥8 to <10 g/dL, n (%) | 34 (27) | 6 (18) |
| Transfusion status, n (%) | ||
| Dependent | 6 (13) | 4 (12) |
| Independent | 109 (87) | 30 (88) |
| Transfusion required ≤12 wk before study entry | 32 (26) | 6 (18) |
| Baseline TSS, median (range) | 17 (0-58) | 14 (0-35) |
| Time from diagnosis to study entry (mo), median (range) | 43 (1-338) | 28 (1-199) |
| Duration of prior ruxolitinib exposure for MF treatment (wk), median (range) | 95 (8-464) | 70 (13-391) |
| DIPSS risk at study entry, n (%) | ||
| Intermediate-1 | 36 (29) | 17 (50) |
| Intermediate-2 | 71 (57) | 12 (35) |
| High | 17 (14) | 4 (12) |
| JAK2 status at study entry, n (%) | ||
| Detected | 84 (72) | 25 (78) |
| CALR status at study entry, n (%) | ||
| Detected | 26 (22) | 7 (22) |
| MPL status at study entry, n (%) | ||
| Detected | 3 (3) | 0 (0) |
| HMR status at study entry† , n (%) | ||
| Detected | 71 (61) | 19 (59) |